Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 3/2017

01-09-2017 | Case Report

Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder) in a Patient with Rheumatoid Arthritis Treated with Methotrexate: Staging and Evaluation of Response to Therapy with 18F-FDG PET/CT

Authors: William Makis, Anthony Ciarallo, Beatrice Wang, Milene Gonzalez-Verdecia, Stephan Probst

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2017

Login to get access

Abstract

A 67 year old woman with a 10 year history of rheumatoid arthritis (RA) treated with methotrexate and prednisone, presented with a 2 year history of worsening multiple cutaneous plaques of variable appearance. Two distinct skin lesions were biopsied to reveal a composite cutaneous lymphoma, possibly caused by long term methotrexate therapy. An [18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) was performed to stage the malignancy, and was later repeated to evaluate response to chemotherapy, which guided subsequent management. We present the PET/CT imaging findings of this very rare iatrogenic (methotrexate induced) immunodeficiency-associated lymphoproliferative disorder.
Literature
1.
go back to reference Huwait H, Wang B, Shustik C, Michel RP. Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Am J Dermatopathol. 2010;32:65–70.CrossRefPubMed Huwait H, Wang B, Shustik C, Michel RP. Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Am J Dermatopathol. 2010;32:65–70.CrossRefPubMed
2.
go back to reference Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood. 2009;114:4337–53.CrossRefPubMed Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood. 2009;114:4337–53.CrossRefPubMed
3.
go back to reference Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.CrossRefPubMed Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.CrossRefPubMed
4.
go back to reference Hull PR, Saxena A. Mycosis fungoides and chronic lymphocytic leukaemia—composite T-cell and B-cell lymphomas presenting in the skin. Br J Dermatol. 2000;143:439–44.CrossRefPubMed Hull PR, Saxena A. Mycosis fungoides and chronic lymphocytic leukaemia—composite T-cell and B-cell lymphomas presenting in the skin. Br J Dermatol. 2000;143:439–44.CrossRefPubMed
5.
go back to reference Volk AL, Vannucci SA, Cook W, Thompson KA, Listinsky CM. Composite mycosis fungoides and B-cell chronic lymphocytic leukemia. Ann Diagn Pathol. 2002;6:172–82.CrossRefPubMed Volk AL, Vannucci SA, Cook W, Thompson KA, Listinsky CM. Composite mycosis fungoides and B-cell chronic lymphocytic leukemia. Ann Diagn Pathol. 2002;6:172–82.CrossRefPubMed
6.
go back to reference Kazakov DV, Kutzner H, Palmedo G, Boudova L, Michaelis S, Michal M, et al. Primary cutaneous lymphoproliferative disorders with dual lineage rearrangement. Am J Dermatopathol. 2006;28:399–409.CrossRefPubMed Kazakov DV, Kutzner H, Palmedo G, Boudova L, Michaelis S, Michal M, et al. Primary cutaneous lymphoproliferative disorders with dual lineage rearrangement. Am J Dermatopathol. 2006;28:399–409.CrossRefPubMed
7.
go back to reference Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740–51.CrossRefPubMed Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740–51.CrossRefPubMed
8.
go back to reference Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26:794–804.CrossRefPubMed Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26:794–804.CrossRefPubMed
9.
go back to reference Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007;82:1106–9.CrossRefPubMed Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007;82:1106–9.CrossRefPubMed
10.
go back to reference Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328:1317–21.CrossRefPubMed Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328:1317–21.CrossRefPubMed
11.
go back to reference Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.CrossRefPubMed Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.CrossRefPubMed
12.
go back to reference Kumar R, Xiu Y, Zhuang HM, Alavi A. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol. 2006;155:357–63.CrossRefPubMed Kumar R, Xiu Y, Zhuang HM, Alavi A. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol. 2006;155:357–63.CrossRefPubMed
13.
go back to reference Makis W, Lisbona R. Aggressive variant of primary cutaneous anaplastic large T-cell lymphoma: a new role for 18F-FDG PET/CT. Clin Nucl Med. 2010;35:704–5.CrossRefPubMed Makis W, Lisbona R. Aggressive variant of primary cutaneous anaplastic large T-cell lymphoma: a new role for 18F-FDG PET/CT. Clin Nucl Med. 2010;35:704–5.CrossRefPubMed
14.
go back to reference Watanabe N, Kato H, Murakami J, Shimizu M, Noguchi K, Kamisaki Y, et al. FDG-PET imaging in cutaneous anaplastic large cell lymphoma. Clin Nucl Med. 2006;31:564–5.CrossRefPubMed Watanabe N, Kato H, Murakami J, Shimizu M, Noguchi K, Kamisaki Y, et al. FDG-PET imaging in cutaneous anaplastic large cell lymphoma. Clin Nucl Med. 2006;31:564–5.CrossRefPubMed
15.
go back to reference Otero HJ, Jagannathan JP, Prevedello LM, Johnston CJ, Ramaiya NH, Van den Abbeele AD, et al. CT and PET/CT findings of T-cell lymphoma. Am J Roentgenol. 2009;193:349–58.CrossRef Otero HJ, Jagannathan JP, Prevedello LM, Johnston CJ, Ramaiya NH, Van den Abbeele AD, et al. CT and PET/CT findings of T-cell lymphoma. Am J Roentgenol. 2009;193:349–58.CrossRef
16.
go back to reference Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613–21.CrossRefPubMed Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613–21.CrossRefPubMed
17.
go back to reference Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685–90.CrossRefPubMed Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685–90.CrossRefPubMed
Metadata
Title
Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder) in a Patient with Rheumatoid Arthritis Treated with Methotrexate: Staging and Evaluation of Response to Therapy with 18F-FDG PET/CT
Authors
William Makis
Anthony Ciarallo
Beatrice Wang
Milene Gonzalez-Verdecia
Stephan Probst
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2017
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0463-4

Other articles of this Issue 3/2017

Nuclear Medicine and Molecular Imaging 3/2017 Go to the issue